Article
[Serum CYFRA21-1 is Correlated with the Efficacy of Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor in Non-small Cell Lung Cancer Patients Harboring EGFR Mutations].
Zhongguo fei ai za zhi = Chinese journal of lung cancer - 20 Aug 2016
Wang Qunhui, Zheng Hua, Hu Fanbin, Zhang Hongmei, Hu Ying, Li Jie, Zhang Tongmei, Liu Zan, Lu Baohua, Hu Aimin, Li Baolan
Abstract excerpt
BACKGROUND: Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are the standard first-line treatment regimen for EGFR mutated non-small cell lung cancer (NSCLC) patients. However, the efficacy of EGFR-TKIs widely varies. The aim of this study is to determine whether the pretreatment serum cytokeratin-19 fragments (CYFRA21-1) and carcinoembryonic antigen (CEA) are associated with the efficacy...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.